Skip to search formSkip to main contentSkip to account menu

AA 673

Known as: AA-673 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
The pharmacodynamics of Amlexanox (AA-673), an azoxanthone derivative recently developed as an ocular anti-allergic drug, were… 
1989
1989
The effect of amlexanox on the non-immunological or immunological release of histamine or leukotrienes (LTs) from passively… 
1989
1989
The inhibitory effect of 0.25% AA-673 eye drops on histamine release in tears was examined by an ocular provocation test with… 
1989
1989
The influences of anti-allergic drugs on superoxide generation from the hypoxanthine-xanthine oxidase system or polymorphonuclear… 
1989
1989
The therapeutic effect and the safety of AA-673 tablets were studied in 31 patients with intractable perennial allergic rhinitis… 
1988
1988
Twenty patients with perennial allergic rhinitis were treated with AA-673 tablets for a mean period of 66 days.Based on the final… 
Highly Cited
1987
Highly Cited
1987
Amlexanox markedly inhibits histamine release from rat mast cells. To clarify the mechanism of this inhibition, we investigated… 
1985
1985
Amoxanox inhibited immunologically stimulated and LTD4-induced bronchoconstriction in laboratory animals. Amoxanox, like DSCG… 
1985
1985
We studied the effects of amoxanox (AA-673) on allergic asthma and spasmogen-induced bronchoconstriction in guinea pigs and rats… 
Highly Cited
1985
Highly Cited
1985
The metabolites and degradation products of 2-amino-7-isopropyl-5-oxo-5H-[1] benzopyrano-[2, 3-b] pyridine-3-carboxylic acid…